$69.37 1.9%
Price vs. AI Score (Last 150 days)
Data gathered: November 29

Data Bits

Data Bits Value / Change Benchmark
Job Posts 2 0%
Sentiment 85 -12.4%
Webpage traffic 79,000 21.3%
Employee Rating 60 0%
Google Adspend $ N/A N/A
Google Trends 26 188.9%
Linkedin Employees 494 N/A
Patents 189 0.5%
4chan Mentions 0%
Stocktwits Mentions 54 3.8%
Stocktwits Subscribers 35,863 0%
Twitter Followers 20,735 0%
Instagram Followers N/A N/A
News Mentions 3 0%
Reddit Mentions 1 0%
Business outlook 43 0%

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

In the news

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.

Crispr Therapeutics
Price $69.37
Target Price Sign up
Market Cap $5.64B
Dividend Yield 0
Industry Biotechnology

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda
Q3 '23018M-18M-112M-132M
Q2 '2370M19M51M-78M-90M
Q1 '23100M22M78M-53M-64M
Q4 '226,00021M-21M-111M-132M
Q3 '2294,00027M-27M-175M-177M

Insider Transactions

Kulkarni Samarth filed to sell 387,377 shares at $66.8.
June 1 '23
Kulkarni Samarth filed to sell 387,377 shares at $51.5.
April 27 '23
Kulkarni Samarth filed to sell 387,377 shares at $44.8.
March 31 '23
Kulkarni Samarth filed to sell 375,988 shares at $49.2.
March 1 '23
Kulkarni Samarth filed to sell 369,111 shares at $51.5.
January 31 '23
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2023 AltIndex. All rights reserved.